Skip to main content
Premium Trial:

Request an Annual Quote

BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection

NEW-YORK ─ BforCure recently announced it has raised €2 million ($2.3 million) from ID-Solutions to adapt its fast in vitro diagnostic PCR platform Chronos Dx to detect cancers.

Chronos Dx leverages BforCure's Fastgene technology to enable a PCR test in less than 15 minutes, the firm said.

The Paris-based point-of-care testing firm said that in the short term it aims to offer a menu of syndromic panels, and in the coming years enter cancer diagnostic testing through its partnership with ID-Solutions, a French biotech company that specializes in oncology diagnostics.

According to BforCure's website, the firm develops platforms based on microfluidics technology for numerous fields including medical diagnostics, defense and security, the food industry, and environmental protection. Fastgene technology reduces PCR cycles from minutes to seconds, the firm added.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.